Concepedia

Belzutifan for Advanced Pheochromocytoma or Paraganglioma

Camilo Jiménez, Mikkel Andreassen, Alice Durand, Sophie Moog, Andrew Hendifar, Staffan Welin, Francesca Spada, Rohini Sharma, Edward M. Wolin, Joseph D. Ruether,

New England Journal of Medicine · 2025 · 10 citations · 14 references

DOIFull text

Open access

Abstract

Belzutifan showed antitumor activity with durable responses in participants with advanced pheochromocytoma or paraganglioma. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; LITESPARK-015 ClinicalTrials.gov number, NCT04924075.).

References

14

Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma

Lauren Fishbein, Ignaty Leshchiner, Vonn Walter et al. · Cancer Cell · 2017 · 750 citations

, , +4

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

New England Journal of Medicine · 2021 · 601 citations · Full text

Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.

Anne‐Paule Gimenez‐Roqueplo, Judith Favier, Pierre Rustin et al. · PubMed · 2003 · 548 citations

, , +11

A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas

Patricia L. M. Dahia, Ken N. Ross, Matthew E. Wright et al. · PLoS Genetics · 2005 · 432 citations · Full text

Efficacy and Safety of High-Specific-Activity <sup>131</sup>I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma

Daniel A. Pryma, Bennett B. Chin, Richard B. Noto et al. · Journal of Nuclear Medicine · 2018 · 272 citations · Full text